Business Today
Subscribe
NRICareer & JobsUS NewsIn PicsWeatherPetrol PricesDiesel PricesPMS TodayBT Reels
Lenovo FIFA World Cup 2026EY Business Today Hidden Gems 2026BT Mindrush
Search
Advertisement
Business News
wockhardt

Wockhardt

 

More Stories on Wockhardt
Pharma stocks: Sun Pharma, Biocon, Dr Reddy's, Torrent Pharma slip on Trump's generic drug tariff plan

Pharma stocks: Sun Pharma, Biocon, Dr Reddy's, Torrent Pharma slip on Trump's generic drug tariff plan

Jul 23, 2026, 10:42 AM IST

Among the notable losers were Sun Pharmaceutical Industries Ltd, Biocon Ltd, Torrent Pharmaceuticals Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd, Wockhardt Ltd, Zydus Lifesciences Ltd, IPCA Laboratories Ltd, Gland Pharma Ltd, Alkem Laboratories Ltd and Ajanta Pharma Ltd.

How Zaynich will drive Wockhardt’s next phase of growth

How Zaynich will drive Wockhardt’s next phase of growth

Jul 07, 2026, 01:56 PM IST

After spending nearly Rs 6,800 crore and more than two decades, Wockhardt has achieved what no Indian pharmaceutical company has before: US FDA approval for a novel drug discovered and developed in-house. Zaynich is expected to drive Wockhardt's next phase of growth after it returned to profitability in FY26.

Full-Circle Moment: Why Vedanta is more than a corporate restructuring story

Full-Circle Moment: Why Vedanta is more than a corporate restructuring story

Jul 06, 2026, 12:39 PM IST

Agarwal’s business journey has come full circle, unlocking value through a deep corporate restructuring.

Here's how this Indian company's antibiotic became the first to receive US FDA

Here's how this Indian company's antibiotic became the first to receive US FDA

Jun 03, 2026, 07:02 PM IST

Wockhardt is betting big on a space the world's largest pharmaceutical companies have abandoned.

Wockhardt R&D Shift: Dr Khorakiwala On How Zaynich Success Transforms Biotech Capital Allocation

Wockhardt R&D Shift: Dr Khorakiwala On How Zaynich Success Transforms Biotech Capital Allocation

Jun 03, 2026, 12:37 PM IST

In an exclusive interview, Wockhardt Founder Chairman Dr. Habil Khorakiwala confirms a major transformation toward becoming a research-driven global biopharma pioneer. Following the breakthrough success and regulatory approvals for its novel antibiotic Zaynich, the company is pivoting its capital allocation strategy to aggressively fund its innovative R&D pipeline over the next three to five years. While global pharma giants scaled back antibiotic research due to weak economic returns, Wockhardt leveraged the lack of competition to target antimicrobial resistance, aiming to establish India as a premier innovation hub for global antibiotic discovery.

Wockhardt Shares Hit Record High As It Secures USFDA Approval For A Novel Antibiotic Zaynich

Wockhardt Shares Hit Record High As It Secures USFDA Approval For A Novel Antibiotic Zaynich

Jun 02, 2026, 03:02 PM IST

Wockhardt Shares Hit Record High As It Secures USFDA Approval For A Novel Antibiotic Zaynich

Zaynich's U.S. FDA Approval Marks Breakthrough For Indian Pharma

Zaynich's U.S. FDA Approval Marks Breakthrough For Indian Pharma

Jun 02, 2026, 02:16 PM IST

Wockhardt has received US FDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The approval follows positive results from the Phase 3 ENHANCE-1 study, where Zaynich demonstrated superior efficacy to meropenem. Wockhardt said Zaynich is the first new chemical entity fully developed and commercialised by an Indian pharmaceutical company to receive U.S. FDA approval. The company recently secured approval for the antibiotic in India and has also submitted a marketing authorisation application in Europe.

Glenmark, Auro Pharma, Wockhardt: Top pharma stocks to trade— Key levels, targets & more

Glenmark, Auro Pharma, Wockhardt: Top pharma stocks to trade— Key levels, targets & more

Jun 02, 2026, 08:36 AM IST

An analyst from Anand Rathi said that Wockhardt has witnessed a strong rally and is currently trading significantly above its 20-day and 50-DEMA, indicating an extended price structure.

Wockhardt share price soars 19% to hit fresh record high; here's why

Wockhardt share price soars 19% to hit fresh record high; here's why

Jun 01, 2026, 09:29 AM IST

Wockhardt share price rose 19.17 per cent to hit a high of Rs 2,420 on BSE. This was in addition to a 14.70 per cent jump on Friday.

Top stocks in news: IndiGo, Lupin, IREDA, HindZinc, NMDC, Cyient, Glenmark, Inox Wind

Top stocks in news: IndiGo, Lupin, IREDA, HindZinc, NMDC, Cyient, Glenmark, Inox Wind

Jun 01, 2026, 07:20 AM IST

Stocks like InterGlobe Aviation, Lupin, IREDA, Hindustan Zinc, NMDC, Cyient, Glenmark Pharma, Inox Wind, Wockhardt, SBI Life will be in the spotlight on Monday, June 01.

Pharma Dominates Small-Cap Winners In May As Wockhardt & Neuland Labs Hit Records

Pharma Dominates Small-Cap Winners In May As Wockhardt & Neuland Labs Hit Records

May 30, 2026, 10:57 PM IST

Pharma Dominates Small-Cap Winners In May As Wockhardt & Neuland Labs Hit Records

MARKET BUZZ

  • NSE
  • BSE
  • No data found
SUBSCRIBE TO
BUSINESS TODAY MAGAZINE
Subscribe Now
Already a subscriber?Login

LATEST

Read more

MARKET TODAY

TOP VIDEOS